Smoking cessation for patients with cardiovascular disease: What is the best approach?

American Journal of Cardiovascular Drugs

Volumn 3, Issue 5, 2003, Pages 339-349

  Joseph, Anne M ^a,b,c   Fu, Steven S ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Minneapolis VA Center for Chronic Disease Outcomes Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; ANTIHISTAMINIC AGENT; CIGARETTE SMOKE; CLONIDINE; CORTICOSTEROID; HYDROCHLOROTHIAZIDE; MECAMYLAMINE; NEUROLEPTIC AGENT; NICOTINE; NICOTINE GUM; NICOTINIC RECEPTOR BLOCKING AGENT; NORTRIPTYLINE; OPIATE; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE; TRAMADOL;

ANAMNESIS; BEHAVIOR MODIFICATION; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; DOSE RESPONSE; DRUG ACTIVITY; DRUG CHOICE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DYSPEPSIA; HICCUP; HUMAN; HYPNOSIS; INSOMNIA; MOTIVATION; MOUTH DISEASE; NICOTINE REPLACEMENT THERAPY; NOSE CONGESTION; PATHOGENESIS; PATIENT COUNSELING; PRIORITY JOURNAL; REVIEW; RHINITIS; RISK FACTOR; SCREENING TEST; SEIZURE; SKIN MANIFESTATION; SLEEP DISORDER; SMOKING CESSATION; SUSTAINED DRUG RELEASE; TOBACCO DEPENDENCE; WEIGHT GAIN; XEROSTOMIA;

CARDIOVASCULAR DISEASES; HUMANS; SMOKING CESSATION;

EID: 0242551499     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200303050-00005     Document Type: Review

References (98)

1. US Department of Health and Human Services. The health consequences of smoking: cardiovascular disease: a report of the Surgeon General. Rockville (MD): Center for Disease Control, 1983
2. American Heart Association. 1998 Heart and stroke statistical update. Dallas (TX): American Heart Association, 1997
3. Fielding J. Smoking: health effects and control (first of two parts). N Engl J Med 1985; 313: 491-8
4. Willett WC, Green A, Stampfer MJ, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987; 317: 1303-9
5. Hallstrom AP, Cobb LA, Ray R. Smoking as a risk factor for recurrence of sudden cardiac arrest. N Engl J Med 1986; 314: 271-5
6. Voors AA, van Brussel BL, Plokker HWT, et al. Smoking and cardiac events after venous coronary bypass surgery. Circulation 1996; 93: 42-7
7. Fellows JL, Trosclair A, Adams EK, et al. Annual smoking: attributable mortality, years of potential life lost, and economic costs: United States 1995-1999. Morb Mortal Wkly Rep 2002; 51: 300-3
8. US Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General. Rockville (MD): Centers for Disease Control, 1990
9. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol 1997; 29 (7): 1422-31
10. Ludviksdottir D, Blondal T, Franzon M, et al. Effects of nicotine nasal spray on atherogenic and thrombogenic factors during smoking cessation. J Intern Med 1999; 246 (1): 61-6
11. Allen SS, Hatsukami D, Gorsline J. Cholesterol changes in smoking cessation using the transdermal nicotine system: Transdermal Nicotine Study Group. Prev Med 1994; 23 (2): 190-6
12. Rosenberg L, Kaufman DW, Helmrich SP, et al. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med 1985; 313 (24): 1511-4
13. Wilson K, Gibson N, Willan A, et al. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000; 160 (7): 939-44
14. Dobson AJ, Alexander HM, Heller RF, et al. How soon after quitting smoking does risk of heart attack decline? J Clin Epidemiol 1991; 44: 1247-53
15. Vliestra RE, Kronmal RA, Oberman A, et al. Effect of cigarette smoking on survival of patients with angiographically documented coronary artery disease. JAMA 1986; 255 (8): 1023-6
16. Morris RW, McCallum AK, Walker M. et al. Cigarette smoking in British men and selection for coronary artery bypass surgery. Heart 1996; 75: 557-62
17. Shelley E. Coronary artery bypass surgery in smokers. Heart 1996; 75 (6): 544-5
18. Missed Opportunities in preventive counseling for cardiovascular disease: United States, 1995. Morb Mortal Wkly Rep 1998; 47 (5): 91-5
19. Fiore MC. The new vital sign: assessing and documenting smoking status. JAMA 1991; 266 (22): 3183-4
20. Attebring ME, Herlitz J, Berndt AK, et al. Are patients truthful about their smoking habits? A validation of self-report about smoking cessation with biochemical markers of smoking activity amongst patients with ischaemic heart disease. J Intern Med 2001; 249: 145-51
21. DiClemente CC, Prochaska JO, Fairhurst SK, et al. The process of smoking cessation: an analysis of precontemplation, contemplation, and preparation stages of change. J Consult Clin Psychol 1991; 59: 295-304
22. Velicer WE, Fava JL, Prochaska JO, et al. Distribution of smokers by stage in three representative samples. Prev Med 1995; 24: 401-11
23. Taylor CB, Houston-Miller N, Killen JD, et al. Smoking cessation after acute myocardial infarction: effects of a nurse-managed intervention. Ann Intern Med 1990; 113 (2): 118-23
24. Ockene J, Kristeller JL, Goldberg R, et al. Smoking cessation and severity of disease: the Coronary Artery Smoking Intervention Study. Health Psychol 1992; 11 (2): 119-26
25. Rigotti NA, McKool KM, Shiffman S. Predictors of smoking cessation after coronary artery bypass graft surgery. Ann Intern Med 1994; 120: 287-93
26. DeBusk RE, Miller NH, Superko HR. et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med 1994; 120 (9): 721-9
27. Dornelas EA, Sampson RA, Gray JF, et al. A randomized controlled trial of smoking cessation counseling after myocardial infarction. Prev Med 2000, 8
28. Crouse III JR, Hagaman AP. Smoking cessation in relation to cardiac procedures. Am J Epidemiol 1991; 134 (7): 699-703
29. Frid D, Ockene IS, Ockene JK, et al. Severity of angiographically proven coronary artery disease predicts smoking cessation. Am J Prev Med 1991: 7 (3): 131-5
30. Campbell IA, Prescott RJ, Tjeder-Burton SM. Transdermal nicotine plus support in patients attending hospital with smoking-related diseases: a placebo-controlled study. Respir Med 1996; 90: 47-51
31. Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease. Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med 1994; 154: 989-95
32. Joseph AM, Norman SM, Ferry LH. et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 335 (24): 1792-8
33. Joseph AM, Antonnucio DO. Lack of efficacy on transdermal nicotine in smoking cessation. N Engl J Med 1999; 341 (15): 1157-8
34. Tzivoni D, Keren A, Meyler S, et al. Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking. Cardiovasc Drugs Ther 1998; 12 (3): 239-44
35. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence. Quick reference guide for clinicians. Rockville, (MD): US Department of Health and Human Services. Public Health Service. October 2000
36. Bovet P, Perret F, Cornuz J, et al. Improved smoking cessation in smokers given ultrasound photographs of their own atherosclerotic plaques. Prev Med 2002; 34: 215-20
37. McHugh F, Lindsay GM, Hanlon P, et al. Nurse led shared care for patients on the waiting list for coronary artery bypass surgery: a randomized controlled trial. Heart (British Cardiac Society) 2001; 86 (3): 317-23
38. Hajek P, West R, Foulds J, et al. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 1999; 159: 2033-8
39. Gourlay SG, Forbes A, Marriner T, et al. Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers. BMJ 1995; 311: 363-6
40. Tonnesen P, Norregaard J, Sawe U, et al. Recycling with nicotine patches in smoking cessation. Addiction 1993; 88: 533-9
41. Hays JT, Croghan IT, Schroeder DR, et al. Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled and open label trials. Am J Public Health 1999; 89 (11): 1701-7
42. Hughes JR, Goldstein MG, Hurt RD, et al. Recent advances in the pharmacotherapy of smoking. JAMA 1999; 281 (1): 72-6
43. Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 2002; 288 (10): 1260-4
44. Tonnesen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trail. Eur Respir J 1999; 13: 238-46
45. Jorenby DE, Smith SS, Fiore MC, et al. Varying nicotine patch dose and type of smoking cessation counseling. JAMA 1995; 274 (17): 1347-52
46. Killen JD, Fortmann SP, Newman B, et al. Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. J Consult Clin Psychol 1990; 58: 85-92
47. Ferris RM, Cooper BR. Mechanism of antidepressant activity of bupropion. J Clin Psychi Mono 1993; 11 (1): 2-14
48. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337 (17): 1195-202
49. Balfour DJ. The pharmacology underlying pharmacotherapy for tobacco dependence: a focus on bupropion. Int J Clin Pract 2001; 55 (1): 53-7
50. Hays JT. Tobacco dependence treatment in patients with heart and lung disease: implications for intervention and review of pharmacological therapy. J Cardiopulm Rehabil 2000; 20 (4): 215-23
51. Pontiere FE, Tanda G, Orzi F, et al. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996; 382: 255-7
52. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295 (1): 321-7
53. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340 (9): 685-91
54. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomized trial. Lancet 2001; 357 (9268): 1571-5
55. Gonzales DH, Nides MA, Ferry LH, et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clin Pharmacol Ther 2001; 69 (6): 438-44
56. Jarvis MJ, Powell SR, Marsh HS, et al. A meta-analysis of clinical studies confirms the effectiveness of bupropion SR (Zyban) in smoking cessation. Poster presentation at Society for Research in Nicotine and Tobacco; 2002
57. Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Ann Intern Med 2001; 135 (6): 423-33
58. Dunner DL, Zisook S, Billow AA, et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998; 59 (7): 366-73
59. Physicians' Desk Reference. 56th ed. Montvale (NJ): Medical Economics Company, 2002
60. Benson E. Bupropion-induced hypersensitivity reactions. Med J Aust 2001; 174 (12): 650-1
61. McCollom RA, Elbe DH, Ritchie AH. Bupropion-induced serum sickness-like reaction. Ann Pharmacother 2000; 34 (4): 471-3
62. Fagerstrom KO. Combined use of nicotine replacement products. Health Values 1994; 18 (3): 15-20
63. Kornitzer M, Bousten M, Thijs J, Gustavsson G. Efficiency and safety of combined use of nicotine patches and nicotine gum in smoking cessation: A placebo controlled double-blind trial [abstract]. Eur Respir J 1993; 6 (17 Suppl.): 630s
64. Kornitzer M, Boutsen M, Dramaix M, et al. Combined use of nicotine patch and gum in smoking cessation. Prev Med 1995; 24: 41-7
65. Puska P, Korhonen H, Vartiainen E, et al. Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Carolina. Tob Control 1995; 4: 231-5
66. Franks P, Hays JT, Bell B. Randomized, controlled trial of clonidine for smoking cessation in a primary care setting. JAMA 1989; 262: 3011-3
67. Prochazka AV, Petty TL, Nett L, et al. Transdermal clonidine reduces some withdrawal symptoms but did not increase smoking cessation. Arch Intern Med 1992; 152: 2065-9
68. Hall SM, Reus VI, Munoz RF, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998; 55 (8): 683-90
69. Glassman AH, Steiner F, Walsh BT, et al. Heavy smokers, smoking cessation, and clonidine: results of a double-blind, randomized trial. JAMA 1988; 259 (19): 2863-6
70. Rose JE, Behm FM, Westman EC. Nicotine-mecamylamine treatment for smoking cessation: the role of the pre-cessation therapy. Exp Clin Psychopharmacol 1998; 6 (3): 331-43
71. Jimenez-Ruiz C, Kunze M, Fagerstrom KO. Nicotine replacement: a new approach to reducing tobacco-related harm. Eur Respir J 1998; 11 (2): 473-9
72. Eliasson B, Hjalmarson A, Kruse E, et al. Effect of smoking reduction and cessation on cardiovascular risk factors. Nicotine Tob Res 2001; 3 (3): 249-55
73. Zevin S, Jacob P, Benowitz NL. Dose-related cardiovascular and endocrine effects of transdermal nicotine. Clin Pharmacol Ther 1998; 64 (1): 87-95
74. Barua RS, Ambrose JA, Eales-Reynolds LJ, et al. Heavy and light cigarette smokers have similar dysfunction of endothelial vasoregulatory activity. J Am Coll Cardiol 2002; 39 (11): 1758-63
75. Huhtasaari F, Lundberg V, Eliasson M, et al. Smokeless tobacco as a possible risk factor for myocardial infarction: a population-based study in middle-aged men. J Am Coll Cardiol 1999; 34 (6): 1784-90
76. Bolinder G, Alfredsson L, Englund A, et al. Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers. Am J Public Health 1994; 84 (3): 399-404
77. Orleans CT, Resch N, Noll E, et al. Use of transdermal nicotine in a state-level prescription plan for the elderly: a first look at 'real-world' patch users. JAMA 1994; 271 (8): 601-7
78. Mahmarian JJ, Moye LA, Nasser GA. et al. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol 1997; 30 (1): 125-30
79. Nitenberg A, Antony I. Effects of nicotine gum on coronary vasomotor responses during sympathetic stimulation in patients with coronary artery stenosis. J Cardiovasc Pharmacol 1999; 34 (5): 694-9
80. Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf 1998; 18 (4): 297-308
81. Murray RP, Bailey WC, Daniels K, et al. Safety of nicotine polacrilex gum used by 3094 participants in the lung health study. Chest 1996; 109: 438-45
82. McRobbie H, Hajek P. Nicotine replacement therapy in patients with cardiovascular disease: guidelines for health professionals. Addiction 2001; 96: 1547-51
83. Tanus-Santos JE, Toledo JCY, Cittadino M, et al. Cardiovascular effects of transdermal nicotine in mildly hypertensive smokers. Am J Hypertens 2001; 14: 610-4
84. Dobson R. Antismoking drug comes under scrutiny after deaths [news]. BMJ 2001; 322 (7284): 452
85. Chapman SC, Jamrozik K. Is bupropion (Zyban) causing deaths [letter]? Med J Aust 2002; 176 (3): 134
86. Patterson RN, Herity NA. Acute myocardial infarction following bupropion (Zyban). Q J Med 2002; 95 (1): 58-9
87. Pederson KJ, Kuntz DH, Garbe GJ. Acute myocardial ischemia associated with ingestion of bupropion and pseudoephedrine in a 21-year-old man. Can J Cardiol 2001; 17 (5): 599-601
88. Dunlop H. Bupropion (Zyban sustained-release tablets): update. CMAJ 2000; 162 (1): 106-7
89. Roose SP, Dalack GW, Glassman AH, et al. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991; 148 (4): 512-6
90. Glassman AH, Preud'homme XA. Review of the cardiovascular effects of heterocyclic antidepressants. J Clin Psychiatry 1993; 54 Suppl. 2: 16-22
91. Kiev A, Masco HL, Wenger TL, et al. The cardiovascular effects of bupropion and nortriptyline in depressed outpatients. Ann Clin Psychiatry 1994; 6 (2): 107-15
92. Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther 1999; 21 (3): 454-63
93. Perruchoud AP, Krause H, Klane MG, et al. Bupropion sustained release (Zyban) is an effective and well tolerated aid to smoking cessation in smokers with cardiovascular disease [abstract]. Circulation 2001; 104 (17) Suppl. 2: ii824
94. Cummings SR, Rubin SM, Oster G. The cost-effectiveness of counseling smokers to quit. JAMA 1989; 26 (1): 75-9
95. Cromwell J, Bartosch WJ, Fiore MC, et al. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation: Agency for Health Care Policy and Research. JAMA 1997; 278 (21): 1759-66
96. Eddy DM. David Eddy ranks the tests. Harv Health Lett 1992; 17 (9): 10-1
97. Krumholz HM, Cohen BJ, Tsevat J, et al. Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol 1993; 22 (6): 1697-702
98. Curry SJ, Grothaus LC, McAfee T, et al. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. N Engl J Med 1998; 339 (10): 673-9